Cargando…
Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis
BACKGROUND: A Phase I, single-center investigation found that 8 weeks of antimycobacterial therapy improved sarcoidosis FVC. Safety and efficacy assessments have not been performed in a multicenter cohort. RESEARCH QUESTION: The objective of this study was to determine the safety and efficacy of ant...
Autores principales: | Drake, Wonder P., Culver, Daniel A., Baughman, Robert P., Judson, Marc A., Crouser, Elliott D., James, W. Ennis, Ayers, Gregory D., Ding, Tan, Abel, Kenny, Green, Abena, Kerrigan, Amy, Sesay, Ahmed, Bernard, Gordon R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129732/ https://www.ncbi.nlm.nih.gov/pubmed/33387486 http://dx.doi.org/10.1016/j.chest.2020.12.027 |
Ejemplares similares
-
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
por: Culver, Daniel A., et al.
Publicado: (2023) -
OUTCOMES IN PATIENTS WITH SARCOIDOSIS DIAGNOSED WITH COVID-19
por: NADEEM, OWAIS, et al.
Publicado: (2021) -
MULTISYSTEM SARCOIDOSIS ASSOCIATED WITH THE COVID-19 MRNA VACCINE
por: MITMA, ANGEL A, et al.
Publicado: (2022) -
PREDICTORS OF POST-COVID-19 PULMONARY FIBROSIS: A CASE SERIES
por: CÎRJALIU, R.-E., et al.
Publicado: (2022) -
CHILDHOOD-ONSET INTERSTITIAL LUNG DISEASE: A RARE CASE OF IDIOPATHIC, NONSPECIFIC INTERSTITIAL PNEUMONIA IN A TEENAGER
por: Cerro, Giuliana, et al.
Publicado: (2020)